J Korean Med Sci.  2016 May;31(5):757-763. 10.3346/jkms.2016.31.5.757.

Serotonin Transporter and COMT Polymorphisms as Independent Predictors of Health-related Quality of Life in Patients with Panic Disorder

• Kang E
• Choe AY
• Kim B
• Lee JY
• Choi TK
• Na HR
• Lee SH

• KMID: 2373674
• DOI: http://doi.org/10.3346/jkms.2016.31.5.757

Abstract

There is growing evidence of poor health-related quality of life (HRQOL) in patients with panic disorder (PD). However, little is known about the factors affecting HRQOL in patients with PD. The authors examined whether 5-HTTLPR tri-allelic approach and Cathechol-O-methyltransferase (COMT) Val(158)Met polymorphism can predict HRQOL in patients with PD controlling for sociodemographic factors and disorder-related symptom levels. The sample consisted of 179 patients with PD consecutively recruited from an outpatient clinic and age- and gender ratio-matched 110 healthy controls. The SF-36 was used to assess multiple domains of HRQOL. Hierarchical multiple regression analysis was performed to determine the independent effect of the 5-HTTLPR and COMT Val(158)Met on the SF-36 in panic patients. Patients with PD showed lowered HRQOL in all sub-domains of the SF-36 compared to healthy controls. The 5-HTTLPR independently and additively accounted for 2.2% of variation (6.7% of inherited variance) of perceived general health and the COMT Val(158)Met independently and additively accounted for 1.5% of variation (5.0% of inherited variance) of role limitation due to emotional problems in patient group. The present study suggests that specific genetic polymorphisms are associated with certain domains of HRQOL and provides a new insight on exploring the factors that predict HRQOL in patients with PD.

Keyword

Quality of Life; Panic Disorder; 5-HTTLPR; COMT Val(158)Met

MeSH Terms

Adult
Age Factors
Alleles
Case-Control Studies
Catechol O-Methyltransferase/*genetics
Female
Genotype
Humans
Male
Middle Aged
Panic Disorder/genetics/*pathology
Polymorphism, Single Nucleotide
*Quality of Life
Regression Analysis
Serotonin Plasma Membrane Transport Proteins/*genetics
Sex Factors
Catechol O-Methyltransferase
Serotonin Plasma Membrane Transport Proteins

Reference

1. Kessler RC, Chiu WT, Jin R, Ruscio AM, Shear K, Walters EE. The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2006; 63:415–424.

2. Klerman GL, Weissman MM, Ouellette R, Johnson J, Greenwald S. Panic attacks in the community. Social morbidity and health care utilization. JAMA. 1991; 265:742–746.

3. Katerndahl DA, Realini JP. Quality of life and panic-related work disability in subjects with infrequent panic and panic disorder. J Clin Psychiatry. 1997; 58:153–158.

4. Rapaport MH, Clary C, Fayyad R, Endicott J. Quality-of-life impairment in depressive and anxiety disorders. Am J Psychiatry. 2005; 162:1171–1178.

5. Sherbourne CD, Wells KB, Judd LL. Functioning and well-being of patients with panic disorder. Am J Psychiatry. 1996; 153:213–218.

6. Davidoff J, Christensen S, Khalili DN, Nguyen J. IsHak WW. Quality of life in panic disorder: looking beyond symptom remission. Qual Life Res. 2012; 21:945–959.

7. Hollifield M, Katon W, Skipper B, Chapman T, Ballenger JC, Mannuzza S, Fyer AJ. Panic disorder and quality of life: variables predictive of functional impairment. Am J Psychiatry. 1997; 154:766–772.

8. Rubin HC, Rapaport MH, Levine B, Gladsjo JK, Rabin A, Auerbach M, Judd LL, Kaplan R. Quality of well being in panic disorder: the assessment of psychiatric and general disability. J Affect Disord. 2000; 57:217–221.

9. Katschnig H, Amering M, Stolk JM, Ballenger JC. Predictors of quality of life in a long-term followup study in panic disorder patients after a clinical drug trial. Psychopharmacol Bull. 1996; 32:149–155.

10. Dimenäs ES, Dahlöf CG, Jern SC, Wiklund IK. Defining quality of life in medicine. Scand J Prim Health Care Suppl. 1990; 1:7–10.

11. Romeis JC, Heath AC, Xian H, Eisen SA, Scherrer JF, Pedersen NL, Fu Q, Bucholz KK, Goldberg J, Lyons MJ, et al. Heritability of SF-36 among middle-age, middle-class, male-male twins. Med Care. 2005; 43:1147–1154.

12. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992; 30:473–483.

13. McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993; 31:247–263.

14. Caspi A, Hariri AR, Holmes A, Uher R, Moffitt TE. Genetic sensitivity to the environment: the case of the serotonin transporter gene and its implications for studying complex diseases and traits. Am J Psychiatry. 2010; 167:509–527.

15. Domschke K, Deckert J, O’donovan MC, Glatt SJ. Meta-analysis of COMT val158met in panic disorder: ethnic heterogeneity and gender specificity. Am J Med Genet B Neuropsychiatr Genet. 2007; 144B:667–673.

16. Kim B, Yoo E, Lee JY, Lee KS, Choe AY, Lee JE, Kwack K, Yook KH, Choi TK, Lee SH. The effects of the catechol-O-methyltransferase val158met polymorphism on white matter connectivity in patients with panic disorder. J Affect Disord. 2013; 147:64–71.

17. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, Benjamin J, Müller CR, Hamer DH, Murphy DL. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 1996; 274:1527–1531.

18. Strug LJ, Suresh R, Fyer AJ, Talati A, Adams PB, Li W, Hodge SE, Gilliam TC, Weissman MM. Panic disorder is associated with the serotonin transporter gene (SLC6A4) but not the promoter region (5-HTTLPR). Mol Psychiatry. 2010; 15:166–176.

19. Blaya C, Salum GA, Lima MS, Leistner-Segal S, Manfro GG. Lack of association between the Serotonin Transporter Promoter Polymorphism (5-HTTLPR) and Panic Disorder: a systematic review and meta-analysis. Behav Brain Funct. 2007; 3:41.

20. Rotondo A, Mazzanti C, Dell’Osso L, Rucci P, Sullivan P, Bouanani S, Gonnelli C, Goldman D, Cassano GB. Catechol o-methyltransferase, serotonin transporter, and tryptophan hydroxylase gene polymorphisms in bipolar disorder patients with and without comorbid panic disorder. Am J Psychiatry. 2002; 159:23–29.

21. Zalsman G, Huang YY, Oquendo MA, Burke AK, Hu XZ, Brent DA, Ellis SP, Goldman D, Mann JJ. Association of a triallelic serotonin transporter gene promoter region (5-HTTLPR) polymorphism with stressful life events and severity of depression. Am J Psychiatry. 2006; 163:1588–1593.

22. Nakamura M, Ueno S, Sano A, Tanabe H. The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants. Mol Psychiatry. 2000; 5:32–38.

23. Kraft JB, Slager SL, McGrath PJ, Hamilton SP. Sequence analysis of the serotonin transporter and associations with antidepressant response. Biol Psychiatry. 2005; 58:374–381.

24. Stein MB, Seedat S, Gelernter J. Serotonin transporter gene promoter polymorphism predicts SSRI response in generalized social anxiety disorder. Psychopharmacology (Berl). 2006; 187:68–72.

25. Neumeister A, Hu XZ, Luckenbaugh DA, Schwarz M, Nugent AC, Bonne O, Herscovitch P, Goldman D, Drevets WC, Charney DS. Differential effects of 5-HTTLPR genotypes on the behavioral and neural responses to tryptophan depletion in patients with major depression and controls. Arch Gen Psychiatry. 2006; 63:978–986.

26. Lachman HM, Morrow B, Shprintzen R, Veit S, Parsia SS, Faedda G, Goldberg R, Kucherlapati R, Papolos DF. Association of codon 108/158 catechol-O-methyltransferase gene polymorphism with the psychiatric manifestations of velo-cardio-facial syndrome. Am J Med Genet. 1996; 67:468–472.

27. Chen J, Lipska BK, Halim N, Ma QD, Matsumoto M, Melhem S, Kolachana BS, Hyde TM, Herman MM, Apud J, et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet. 2004; 75:807–821.

28. First MB, Spitzer RL, Gibbon M, Williams JB. Structured Clinical Interview for DSM-IV Axis I Disorders (SCID). Washington, D.C.: American Psychiatric Press;1996.

29. Nam BH, Lee SW. Testing the validity of the Korean SF-36 health survey. J Korean Soc Health Stat. 2003; 28:3–24.

30. Lim YJ, Yu BH, Kim JH. Korean panic disorder severity scale: construct validity by confirmatory factor analysis. Depress Anxiety. 2007; 24:95–102.

31. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961; 4:561–571.

32. Lonsdorf TB, Weike AI, Nikamo P, Schalling M, Hamm AO, Ohman A. Genetic gating of human fear learning and extinction: possible implications for gene-environment interaction in anxiety disorder. Psychol Sci. 2009; 20:198–206.

33. Kim H, Lim SW, Kim S, Kim JW, Chang YH, Carroll BJ, Kim DK. Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression. JAMA. 2006; 296:1609–1618.

34. Choe AY, Kim B, Lee KS, Lee JE, Lee JY, Choi TK, Lee SH. Serotonergic genes (5-HTT and HTR1A) and separation life events: gene-by-environment interaction for panic disorder. Neuropsychobiology. 2013; 67:192–200.

35. Trivedi MH, Rush AJ, Wisniewski SR, Warden D, McKinney W, Downing M, Berman SR, Farabaugh A, Luther JF, Nierenberg AA, et al. Factors associated with health-related quality of life among outpatients with major depressive disorder: a STAR*D report. J Clin Psychiatry. 2006; 67:185–195.

36. Franco OH, Wong YL, Kandala NB, Ferrie JE, Dorn JM, Kivimäki M, Clarke A, Donahue RP, Manoux AS, Freudenheim JL, et al. Cross-cultural comparison of correlates of quality of life and health status: the Whitehall II Study (UK) and the Western New York Health Study (US). Eur J Epidemiol. 2012; 27:255–265.

37. Woo JM, Yoon KS, Yu BH. Catechol O-methyltransferase genetic polymorphism in panic disorder. Am J Psychiatry. 2002; 159:1785–1787.